By Carlo Martuscelli
Smith & Nephew PLC (SN.LN) said Thursday that revenue in the third quarter rose 2% and backed its full-year guidance.
The company said revenue for the quarter ended Sept. 29 was $1.17 billion, and rose 3% on an underlying basis compared with the previous year.
It attributed the underlying growth to its performance in the U.S. and emerging markets.
The advanced wound bioactives division continued to decline, although growth in reconstruction, sports-medicine joint repair and advanced wound devices was strong, the FTSE-100 listed medical-equipment manufacturer said.